Last moves
Peptide Exchange
0molecules on your watchlist

Incretins

Orforglipron

Brand Foundayo

Lilly's oral GLP-1 pill, approved by the FDA in April 2026 for weight management. The ACHIEVE programme tests it in type 2 diabetes.

Orforglipron comes from Eli Lilly and sits in the Incretins class on the board. Route: daily pill. Use tracked here: Chronic weight management in adults with obesity or overweight (US approved); type 2 diabetes (under study in the US). It stands at Approved on the board, with 3 news moves logged; the latest is dated 31 Oct 2026.

  1. 05ApprovedHere now
  2. 04FiledApplication submitted to a regulator and under review.
  3. 03Phase 3Large confirmatory trials meant to support a filing.
  4. 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
  5. 01Phase 1First doses in people. Safety, dose range, how the body handles it.
Company
Eli Lilly
Mechanism
Small molecule, non-peptide GLP-1 receptor agonist taken by mouth without food or water restrictions
Given as
daily pill
Lead use on the board
Chronic weight management in adults with obesity or overweight (US approved); type 2 diabetes (under study in the US)
Moves logged
3latest 3 days ago

Orforglipron news moves

  1. ■ ExplainerHolds APP

    Foundayo sales miss forecasts as tirzepatide keeps Lilly ahead

    Lilly's orforglipron pill nearly doubled its revenue but missed Wall Street by 44 million dollars, while weekly tirzepatide injections brought in about 16.1 billion dollars. The oral GLP 1 race has barely started.

  2. ▲ ApprovalHolds APP

    Orforglipron CHMP opinion puts the Foundayo pill on course for an EU licence

    The EMA committee recommended Lilly's once daily non peptide GLP-1 tablet for weight management and type 2 diabetes. Weight fell about 5 to 11 percent at 72 weeks, and the Commission decision and national pricing come next.

  3. ■ ReadoutHolds APP

    Orforglipron vs oral semaglutide indirect comparison gives Lilly a narrow edge

    A Lilly funded analysis bridging ACHIEVE-3 and PIONEER PLUS credits orforglipron with slightly more weight loss and HbA1c lowering in type 2 diabetes. It is a modelled comparison, and Novo has one pointing the other way.